| | Zolpidem Basic information |
| Product Name: | Zolpidem | | Synonyms: | ZOLPIDEM >96% IMIDAZOPYRIDINE DERIV;N,N,6-Trimethyl-2-(4-methylphenyl)imidazo[1,2-a]pyrimidine-3-acetamide, SL-80.0750;6-methyl-N,N-dimethyl-2-(4-methyl-phenyl)-imidazo[1,2-a]pyridine-3-yl]-acetamide (intermediate of zolpidem);N,N-dimethyl-2-[3-methyl-8-(4-methylphenyl)-1,7-diazabicyclo[4.3.0]nona-2,4,6,8-tetraen-9-yl]acetamide;6-METHYL-N,N-DIMETHYL-2-(4-METHYL-PHENYL)-IMIDAZO[1,2-A]PYRIDINE-3-YL]-ACETAMIDE;2-(4-Methylphenyl)-6-Methylimidazo(1,2,a)Pyridine;2-a)pyridine-3-acetamide,2-(4-methylphenyl)-n,n,6-trimethyl-imidazo(;N,N,6-Trimethyl-2-p-tolylimidazo[1,2-a]pyridine-3-acetamide | | CAS: | 82626-48-0 | | MF: | C19H21N3O | | MW: | 307.39 | | EINECS: | | | Product Categories: | Amines;Heterocycles;Intermediates & Fine Chemicals;Pharmaceuticals;Isotopically Labeled Pharmaceutical Reference Standard;Pyridines derivates;Zolpidem;(intermediate of zolpidem) | | Mol File: | 82626-48-0.mol |  |
| | Zolpidem Chemical Properties |
| Melting point | 189-191°C | | density | 1.12±0.1 g/cm3(Predicted) | | Fp | 9℃ | | storage temp. | Store at RT | | solubility | 45% (w/v) aq 2-hydroxypropyl-β-cyclodextrin: 0.3 mg/mL | | pka | 6.2(at 25℃) | | form | solid | | color | white | | Water Solubility | <10mg/L(room temperature) | | Major Application | clinical testing | | InChI | 1S/C19H21N3O/c1-13-5-8-15(9-6-13)19-16(11-18(23)21(3)4)22-12-14(2)7-10-17(22)20-19/h5-10,12H,11H2,1-4H3 | | InChIKey | ZAFYATHCZYHLPB-UHFFFAOYSA-N | | SMILES | [n]21c(nc(c2CC(=O)N(C)C)c3ccc(cc3)C)ccc(c1)C | | CAS DataBase Reference | 82626-48-0(CAS DataBase Reference) | | NIST Chemistry Reference | Zolpidem(82626-48-0) |
| Hazard Codes | Xi | | Risk Statements | 36/37/38 | | Safety Statements | 26-36 | | RIDADR | UN1230 - class 3 - PG 2 - Methanol, solution | | WGK Germany | 3 | | RTECS | NJ5109750 | | HS Code | 2933996500 | | Storage Class | 3 - Flammable liquids | | Hazard Classifications | Acute Tox. 3 Dermal
Acute Tox. 3 Inhalation
Acute Tox. 3 Oral
Flam. Liq. 2
STOT SE 1 |
| | Zolpidem Usage And Synthesis |
| Description | Zolpidem hemitamwe is a non-benzodiazepine hypnotic with specific agonist activity at
type 1 benzodiazepine receptors, and is indicated for use in insomnia and other sleep
disorders. Structurally zolpidem belongs to a chemically distinct class, thus lacking the
side-effects and abuse potential of classical benzodiazepines. It is currently being studied
as a pre-operative sedative. | | Description | Zolpidem (Item No. 15792) is an analytical reference material that is functionally categorized as a sedative. It is a non-benzodiazepine drug that is used in the treatment of insomnia, and it has been recreationally abused. This product is intended for research and forensic applications. | | Description | Zolpidem (Item No. 20648) is a certified reference material that is functionally categorized as a sedative. It is a non-benzodiazepine drug that is used in the treatment of insomnia, and it has been recreationally abused. This product is intended for research and forensic applications. | | Chemical Properties | Off-White Solid | | Originator | Synthelabo (France) | | Uses | A selective benzodiazepine receptor agonist not related chemically to benzodiazepines | | Uses | A selective non-benzodiazepine GABAA receptor agonist. Sedative, hypnotic.
Controlled substance (depresssant). | | Definition | ChEBI: An imidazo[1,2-a]pyridine compound having a 4-tolyl group at the 2-position, an N,N-dimethylcarbamoylmethyl group at the 3-position and a methyl substituent at the 6-position. | | Brand name | Ambien (Sanofi Aventis);Stilnox. | | General Description | Zolpidem (Ambien, an imidazopyridine) andeszopiclone (Lunesta, a cyclopyrrolone) are nonbenzodiazepinesand have been introduced as short- and moderate-acting hypnotics, respectively. Zolpidem exhibits ahigh selectivity for the α1 subunit of benzodiazepinebindingsite on GABAA receptor complex, whereas eszopicloneis a “superagonist” at BzRs with the subunitcomposition α1β2γ2 and α1β2γ3. Zolpidem has a rapidonset of action of 1.6 hours and good bioavailability(72%), mainly because it is lipophilic and has no ionizablegroups at physiological pH. Food can prolong the time topeak concentration without affecting the half-life probablyfor the same reason. It has short elimination half-life, becauseits aryl methyl groups is extensively α-hydroxylatedto inactive metabolites by CYP3A4 followed by furtheroxidation by aldehyde dehydrogenase to the ionic carboxylicacid. The metabolites are inactive, short-lived, andeliminated in the urine. Its half-life in the elderly or the patientswith liver disease is increased. Therefore, dosingshould be modified in patients with hepatic insufficiencyand the elderly. Because it has longer elimination half-lifethan zaleplon, it may be preferred for sleep maintenance.It was the most commonly prescribed drug for insomniain 2001. | | References | [1] S ARBILLA. Pharmacological profile of the imidazopyridine zolpidem at benzodiazepine receptors and electrocorticogram in rats.[J]. Naunyn-Schmiedeberg’s archives of pharmacology, 1985, 330 3: 248-251. DOI: 10.1007/bf00572441
[2] MARJORIE CHèZE. Hair analysis by liquid chromatography–tandem mass spectrometry in toxicological investigation of drug-facilitated crimes: Report of 128 cases over the period June 2003–May 2004 in metropolitan Paris[J]. Forensic science international, 2005, 153 1: Pages 3-10. DOI: 10.1016/j.forsciint.2005.04.021 |
| | Zolpidem Preparation Products And Raw materials |
| Raw materials | Methylamine-->Oxalyl chloride-->Acetamide, 2-diazo-N,N-dimethyl--->6-Methyl-2-(4-methylphenyl)imidazo[1,2-a]pyridine-->2-Bromo-N,N-dimethylacetamide-->2-PropynaMide, N,N-diMethyl--->6-Methyl-2-(4-methylphenyl)imidazol[1,2-a]-pyridine-3-acetic acid-->Benzenebutanamide, β-bromo-N,N,4-trimethyl-γ-oxo--->Dimethylamine-->Dimethylamine hydrochloride-->2-Amino-5-methylpyridine | | Preparation Products | 6-METHYL-N,N-DIMETHYL-2-(4-METHYLPHENYL)-2-HYDROXYIMIDAZO[1,2-ALPHA]PYRIDINE-3-ACETAMIDE |
|